Stockscreener 앱 받기
19.90
0.20%
-0.04
시간 외 거래:
19.90
전일 마감가:
$19.94
열려 있는:
$19.99
하루 거래량:
834.26K
Relative Volume:
0.54
시가총액:
$1.76B
수익:
$217.42M
순이익/손실:
$-243.25M
주가수익비율:
-7.1193
EPS:
-2.7952
순현금흐름:
$-278.35M
1주 성능:
+2.79%
1개월 성능:
-6.97%
6개월 성능:
+0.15%
1년 성능:
+102.03%
1일 변동 폭
$19.66
$20.36
1주일 범위
$19.40
$20.55
52주 변동 폭
$8.585
$25.59
Syndax Pharmaceuticals Inc Stock (SNDX) Company Profile
명칭
Syndax Pharmaceuticals Inc
전화
781-419-1400
주소
730 THIRD AVENUE, NEW YORK, MA
Compare SNDX vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SNDX
Syndax Pharmaceuticals Inc
|
19.90 | 1.77B | 217.42M | -243.25M | -278.35M | -2.7952 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Syndax Pharmaceuticals Inc Stock (SNDX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-16 | 재개 | H.C. Wainwright | Buy |
| 2025-09-10 | 재개 | Stifel | Buy |
| 2025-09-04 | 재개 | Guggenheim | Buy |
| 2025-08-05 | 재확인 | BTIG Research | Buy |
| 2025-07-10 | 개시 | Goldman | Buy |
| 2024-10-24 | 개시 | UBS | Buy |
| 2024-06-28 | 개시 | Jefferies | Buy |
| 2024-01-31 | 다운그레이드 | Scotiabank | Sector Outperform → Sector Perform |
| 2023-12-22 | 개시 | Mizuho | Buy |
| 2023-10-25 | 개시 | BofA Securities | Buy |
| 2023-10-11 | 개시 | Goldman | Buy |
| 2023-07-27 | 개시 | Scotiabank | Sector Outperform |
| 2023-07-11 | 개시 | Guggenheim | Buy |
| 2023-04-17 | 재개 | BTIG Research | Buy |
| 2023-01-31 | 개시 | Stifel | Buy |
| 2023-01-03 | 개시 | JP Morgan | Overweight |
| 2022-07-28 | 재개 | B. Riley Securities | Buy |
| 2022-04-11 | 개시 | H.C. Wainwright | Buy |
| 2022-02-15 | 개시 | Goldman | Buy |
| 2021-06-04 | 재개 | Robert W. Baird | Outperform |
| 2021-05-25 | 개시 | Citigroup | Buy |
| 2021-02-18 | 개시 | B. Riley Securities | Buy |
| 2020-12-03 | 개시 | Stifel | Buy |
| 2020-05-22 | 업그레이드 | Citigroup | Neutral → Buy |
| 2020-05-22 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2020-05-18 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-05-11 | 재확인 | H.C. Wainwright | Buy |
| 2020-03-04 | 개시 | Barclays | Overweight |
| 2020-01-13 | 재확인 | H.C. Wainwright | Buy |
| 2019-03-08 | 재확인 | H.C. Wainwright | Buy |
| 2019-01-04 | 개시 | Robert W. Baird | Outperform |
| 2018-01-05 | 개시 | B. Riley FBR, Inc. | Buy |
| 2017-03-16 | 개시 | FBR & Co. | Outperform |
| 2017-03-02 | 개시 | Instinet | Buy |
| 2016-10-07 | 개시 | Guggenheim | Buy |
| 2016-03-28 | 개시 | Citigroup | Buy |
| 2016-03-28 | 개시 | JMP Securities | Mkt Outperform |
| 2016-03-28 | 개시 | Morgan Stanley | Overweight |
모두보기
Syndax Pharmaceuticals Inc 주식(SNDX)의 최신 뉴스
Assessing Whether Syndax Pharmaceuticals (SNDX) Looks Undervalued After Recent Share Price Weakness - Yahoo Finance
SNDX Reiterates by HC Wainwright & Co. -- Price Target Maintained at $40 - GuruFocus
H.C. Wainwright Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Maintains Target Price $40 - Moomoo
Assessing Syndax Pharmaceuticals (SNDX) Valuation After New Revuforj Leukemia Data Spurs Investor Interest - Sahm
Syndax Pharmaceuticals to Present Key Revumenib Data at ASCO 2026, Highlighting Post-Transplant Outcomes and Pharmacokinetic Insights - Quiver Quantitative
Leukemia drug revumenib data to headline 4 ASCO 2026 talks - Stock Titan
BofA Securities Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Maintains Target Price $29 - Moomoo
Syndax Pharmaceuticals’ SWOT analysis: stock gains momentum on strong launch - Investing.com UK
Syndax Announces Participation in Upcoming Investor Conferences - 富途牛牛
Which Is a Better Investment, Syndax Pharmaceuticals, Inc. or Sarepta Therapeutics, Inc. Stock? - AAII
Point72 (SNDX) reports 1,985,547 shares, 2.3% stake in Syndax - Stock Titan
(SNDX) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Does Expanded Revuforj Leukemia Data Set Change The Bull Case For Syndax Pharmaceuticals (SNDX)? - Sahm
Why Syndax Pharmaceuticals (SNDX) is One of the Best Small Cap Stocks to Buy for 10x Potential - Insider Monkey
UBS Trims Price Target on Syndax Pharmaceuticals to $37 From $38, Maintains Buy Rating - Moomoo
UBS Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Cuts Target Price to $37 - Moomoo
SNDX Maintained by UBS -- Price Target Lowered to $37.00 - GuruFocus
Syndax (SNDX) Highlights Revuforj Data Ahead of EHA Congress - GuruFocus
Syndax Pharmaceuticals stock (US88906L1052): Analyst upgrade drives 6.6% gain - AD HOC NEWS
Syndax Highlights 12 Revuforj® (revumenib) Abstracts Accepted for EHA 2026, Advancing Leadership in Menin Inhibition - The Manila Times
Syndax Highlights 12 Revuforj® (revumenib) Abstracts - GlobeNewswire
Leukemia drug revumenib lands 12 studies at European Hematology meeting - Stock Titan
TradingKey - TradingKey
Assessing Syndax Pharmaceuticals (SNDX) Valuation After Stronger Revenue And Narrower Losses - simplywall.st
SNDX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Syndax Pharmaceuticals (SNDX): Analyst Ratings Suggest A 92% Upside Potential - DirectorsTalk Interviews
SNDX Stock Price, Quote & Chart | SYNDAX PHARMACEUTICALS INC (NASDAQ:SNDX) - ChartMill
SNDX SEC FilingsSyndax Pharmaceuticals Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - The Manila Times
Eight new Syndax hires get stock options for 162,100 shares - Stock Titan
MSN Money - MSN
Stifel Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Raises Target Price to $46 - Moomoo
Syndax Pharmaceuticals, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:SNDX) 2026-05-05 - Seeking Alpha
HC Wainwright Has Optimistic Outlook of SNDX Q2 Earnings - MarketBeat
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) First-Quarter Results: Here's What Analysts Are Forecasting For This Year - simplywall.st
(SNDX) Risk Channels and Responsive Allocation - Stock Traders Daily
Biotech Momentum Builds As Syndax Pharmaceuticals Draws Market Attention - Kalkine Media
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Just Released Its First-Quarter Earnings: Here's What Analysts Think - 富途牛牛
Syndax Pharmaceuticals (NASDAQ:SNDX) Stock Price Up 6.6% Following Analyst Upgrade - MarketBeat
Stifel raises Syndax Pharmaceuticals stock price target on therapy outlook By Investing.com - Investing.com Canada
Stifel raises Syndax Pharmaceuticals stock price target on therapy outlook - Investing.com
HC Wainwright Has Optimistic Outlook of SNDX FY2030 Earnings - MarketBeat
Syndax Pharmaceuticals (SNDX) Is Down 10.7% After Revenue Surges And Loss Narrows In Q1 2026 - simplywall.st
Syndax Pharmaceuticals (SNDX) Narrows Q1 Loss To US$42.7 Million Challenging Bearish Narratives - Sahm
Net current asset value per share of Syndax Pharmaceuticals Inc – DUS:1T3 - TradingView
Syndax Pharmaceuticals Q1 Loss Narrows, Revenue Rises - Moomoo
Syndax Pharmaceuticals Reports Over $100 Million in Q1 Combined Sales - HarianBasis.co
Analysts Have Conflicting Sentiments on These Healthcare Companies: Centene (CNC) and Syndax Pharmaceuticals (SNDX) - The Globe and Mail
Jefferies Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Cuts Target Price to $37 - Moomoo
Syndax Pharmaceuticals 1Q Loss $42.7M >SNDX - Moomoo
Syndax (SNDX) Narrows Losses as Revuforj and Niktimvo Gain TractionWhat’s Really Shifting? - Yahoo Finance UK
Syndax Pharmaceuticals Inc (SNDX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.98%
0.12%
자본화:
|
볼륨(24시간):